Drug intelligence / Profile preview

technetium-99m PSMA-11

Development stage: Unknown
Lead developer: AIIMS Bhubaneswar
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptides
Administration: Intravenous

Overview

Technetium-99m PSMA-11 (Tc-99m PSMA-11) is a diagnostic radiopharmaceutical and SPECT imaging agent designed to target prostate-specific membrane antigen (PSMA), which is highly overexpressed in prostate cancer cells. It consists of the gamma-emitting radioisotope technetium-99m conjugated to the peptidomimetic urea-based PSMA inhibitor PSMA-11 (also known as gozetotide) via the chelator HBED-CC. Tc-99m PSMA-11 is used for the detection, staging, and restaging of prostate carcinoma, particularly in identifying primary lesions and bone or lymph node metastases. It serves as a cost-effective and widely accessible alternative to gallium-68 (Ga-68) PSMA PET/CT imaging, especially in resource-limited settings where PET infrastructure is unavailable.

Other names: 99mTc-PSMA-1199mTc-PSMA-HBED-CCTc-99m PSMA-11Tc99m PSMA-11Tc 99m PSMA-11Tc-99m PSMA-HBED-CCTc99m PSMA-HBED-CCTc 99m PSMA-HBED-CCtechnetium-99m PSMA-HBED-CCtechnetium99m PSMA-HBED-CCtechnetium 99m PSMA-HBED-CCtechnetium-99m-labeled PSMA-11technetium99m-labeled PSMA-11technetium 99m-labeled PSMA-11

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on technetium-99m PSMA-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium-99m PSMA-11.